Table 2.
Demographic data and clinical characteristics of the transplanted patients included in the B lymphocyte monitoring study.
| RTR (n = 41) n (%) |
NAR (n = 36) n (%) |
AR (n = 5) n (%) |
p a | |
|---|---|---|---|---|
| Age (years; mean ± SEM) | 56.6 ± 2.5 | 57.7 ± 1.6 | 51 ± 7.9 | 0.449 |
| Gender (Male/Female) | (28/13) | (23/13) | 5 (5/0) | 0.104 |
| IncompatibilitiesHLA b | 3.9 ± 0.4 | 3.8 ± 0.2 | 4.0 ± 1.1 | 0.548 |
| Live Donor (%) | 2 (4.8) | 2 (5.5) | 0 (0) | 0.589 |
| Preformed anti-HLA antibodies (%) | 5 (12.2) | 5 (13.8) | 0 (0) | 0.374 |
| Induction Therapy (Tim/Bas) | 19 (14/5) | 17 (12/5) | 2 (2/0) | 1.000 |
| Delayed graft function (%) | 13 (29.3) | 12 (33.3) | 1 (20) | 1.000 |
| Type of rejection (Cellular/Humoral) | 5 (4/1) | - | 5 (4/1) | - |
NRA, No Acute Rejection; RA, Acute Rejection; RTR, Renal transplant recipient; SEM, standard error of the mean. Tim, Thymoglobulin; Bas, Basiliximab. Quantitative data expressed as the mean ± standard error of the mean (SEM). a Comparisons were made using Fisher’s exact test or X2 for qualitative variables and using the nonparametric Mann-Whitney U test for quantitative variables. Values of p < 0.05 were considered statistically significant. b Total differences between donor and recipient concerning the HLA-A. HLA-B and HLA-DRB1 genes.